Alder Biopharmaceuticals Inc (NASDAQ:ALDR) – Stock analysts at Leerink Swann issued their FY2020 earnings per share (EPS) estimates for Alder Biopharmaceuticals in a report issued on Friday. Leerink Swann analyst G. Porges expects that the biopharmaceutical company will earn ($3.32) per share for the year. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Alder Biopharmaceuticals’ FY2021 earnings at ($0.71) EPS and FY2022 earnings at ($0.19) EPS.
Several other equities research analysts have also recently weighed in on the stock. BidaskClub upgraded shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Zacks Investment Research upgraded shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Cowen set a $23.00 price target on shares of Alder Biopharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 26th. ValuEngine cut shares of Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Mizuho restated a “buy” rating and issued a $29.00 price target on shares of Alder Biopharmaceuticals in a research report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $28.14.
Shares of Alder Biopharmaceuticals stock opened at $14.15 on Monday. Alder Biopharmaceuticals has a 1 year low of $8.60 and a 1 year high of $23.35. The firm has a market cap of $960.00, a price-to-earnings ratio of -2.73 and a beta of 2.51.
Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.23. The business had revenue of $0.94 million during the quarter. During the same quarter in the previous year, the company earned ($0.97) EPS.
Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in Alder Biopharmaceuticals during the fourth quarter worth $132,000. Jane Street Group LLC purchased a new stake in shares of Alder Biopharmaceuticals during the third quarter valued at $184,000. Paloma Partners Management Co purchased a new stake in shares of Alder Biopharmaceuticals during the fourth quarter valued at $222,000. Teacher Retirement System of Texas purchased a new stake in shares of Alder Biopharmaceuticals during the fourth quarter valued at $231,000. Finally, Cubist Systematic Strategies LLC boosted its stake in shares of Alder Biopharmaceuticals by 611.7% during the third quarter. Cubist Systematic Strategies LLC now owns 23,373 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 20,089 shares during the period. 99.14% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/19/alder-biopharmaceuticals-inc-aldr-expected-to-earn-fy2020-earnings-of-3-32-per-share.html.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.